Live Breaking News & Updates on Professor Mikael Mazighi

Stay updated with breaking news from Professor mikael mazighi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Acticor Biotech Announces Publication of ACTIMIS Clinical Study Results in the Lancet Neurology Journal

ACTICOR BIOTECH announced the publication of phase 1b/2a clinical results of ACTIMIS study in The Lancet Neurology Journal. The manuscript is entitled: Safety and efficacy of platelet glycoprotein VI. ....

European Stroke Organisation Conference , Lancet Neurology , Acute Ischemic , Professor Mikael Mazighi ,

Acticor Biotech Announces Its 2022 Half-year Financial Results and Update on Its Clinical Progress

Significant clinical progress in the treatment of stroke with glenzocimab: Positive results from the ACTIMIS phase 1b/2a study Patent granted to protect glenzocimab in thrombotic ....

United States , France General , United Kingdom , Czech Republic , Great Britain , Newton Biocapital , Gilles Avenard , Mikael Mazighi , Corinne Le Goff , Ruchira Shah , European Patent Office , Venture Investment , Neuroscience Center , French National Institute Of Health , Drug Administration , Net Research , Given The Company , European Medicines Agency , Regulated Information , Chief Executive Officer , Acticor Biotech , Assistance Publique H , Fast Track , Acute Ischemic Stroke , Professor Mikael Mazighi , Coordinating Investigator ,

ACTICOR BIOTECH: Presentation of Positive Results From the ACTIMIS Phase 1b/2a Study in Stroke at ESOC 2022

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT), a clinical-stage biotechnology company developing an innovative drug for the treatment of cardiovascular emergencies,announces today the ....

Newton Biocapital , Mikael Mazighi , Venture Investment , European Stroke Organisation Conference , French National Institute Of Health , European Stroke Organisation , Regulatory News , Friday May , Professor Mikael Mazighi , Coordinating Investigator , Ceremony Large Clinical Trials , Novel Antithrombotic , Reduced Intracranial Hemorrhage , Mortality Rates , Standard Of Care Reperfusion Therapies , French National Institute , Medical Research , Mirae Asset Capital , Primer Capital , Acticor Biotech , Euronext Growth Paris , Stroke Journal ,